Literature DB >> 8985659

Novel mechanism of macrolide resistance in Streptococcus pneumoniae.

V D Shortridge1, R K Flamm, N Ramer, J Beyer, S K Tanaka.   

Abstract

The mechanism of macrolide resistance was examined in 73 clinical isolates of Streptococcus pneumoniae. Two distinct resistance phenotypes were observed: high-level macrolides-lincosamides-streptogramin B (MLS) resistance and low-level macrolide resistance with lincosamide susceptibility. High-level MLS resistance was associated with the presence of ermAM. Strains with the low-level resistant phenotype (novel) were negative for ermA, ermC, ermAM, ereA, ereB and msrA by polymerase chain reaction (PCR) amplification with gene-specific primers. Ribosomes isolated from novel strains bound the same amount of [14C]-erythromycin as ribosomes from sensitive strains. These novel strains also did not inactivate the macrolide. The novel mechanism was found in 41% of the erythromycin resistant S. pneumoniae examined.

Entities:  

Mesh：

Substances：

Year:  1996        PMID： 8985659     DOI： 10.1016/s0732-8893(96)00183-6

Source DB:  PubMed          Journal:  Diagn Microbiol Infect Dis        ISSN： 0732-8893            Impact factor:   2.803


  35 in total

Review 1.  Nomenclature for macrolide and macrolide-lincosamide-streptogramin B resistance determinants.

Authors:  M C Roberts; J Sutcliffe; P Courvalin; L B Jensen; J Rood; H Seppala
Journal:  Antimicrob Agents Chemother       Date:  1999-12       Impact factor: 5.191

Review 2.  Molecular detection of antimicrobial resistance.

Authors:  A C Fluit; M R Visser; F J Schmitz
Journal:  Clin Microbiol Rev       Date:  2001-10       Impact factor: 26.132

3.  Comparative in vitro activity of ABT-773, a novel antibacterial ketolide.

Authors:  A M Nilius; M H Bui; L Almer; D Hensey-Rudloff; J Beyer; Z Ma; Y S Or; R K Flamm
Journal:  Antimicrob Agents Chemother       Date:  2001-07       Impact factor: 5.191

4.  Presence of mefA and mefE genes in Streptococcus agalactiae.

Authors:  C Arpin; H Daube; F Tessier; C Quentin
Journal:  Antimicrob Agents Chemother       Date:  1999-04       Impact factor: 5.191

5.  Molecular epidemiology of macrolide resistance in neonatal bloodstream isolates of group B streptococci.

Authors:  Daniel J Diekema; Janet I Andrews; Holly Huynh; Paul R Rhomberg; Stella R Doktor; Jill Beyer; Virginia D Shortridge; Robert K Flamm; Ronald N Jones; Michael A Pfaller
Journal:  J Clin Microbiol       Date:  2003-06       Impact factor: 5.948

6.  Antimicrobial resistance among clinical isolates of Streptococcus pneumoniae in the United States during 1999--2000, including a comparison of resistance rates since 1994--1995.

Authors:  G V Doern; K P Heilmann; H K Huynh; P R Rhomberg; S L Coffman; A B Brueggemann
Journal:  Antimicrob Agents Chemother       Date:  2001-06       Impact factor: 5.191

7.  Antimicrobial susceptibilities of invasive pediatric Abiotrophia and Granulicatella isolates.

Authors:  Xiaotian Zheng; Alexandra F Freeman; Jay Villafranca; Dee Shortridge; Jill Beyer; William Kabat; Karen Dembkowski; Stanford T Shulman
Journal:  J Clin Microbiol       Date:  2004-09       Impact factor: 5.948

8.  In vitro activity of ABT-773, a new ketolide, against recent clinical isolates of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis.

Authors:  A B Brueggemann; G V Doern; H K Huynh; E M Wingert; P R Rhomberg
Journal:  Antimicrob Agents Chemother       Date:  2000-02       Impact factor: 5.191

9.  Clarithromycin Resistance Mechanisms of Epidemic β-Lactamase-Nonproducing Ampicillin-Resistant Haemophilus influenzae Strains in Japan.

Authors:  Shoji Seyama; Takeaki Wajima; Hidemasa Nakaminami; Norihisa Noguchi
Journal:  Antimicrob Agents Chemother       Date:  2016-04-22       Impact factor: 5.191

10.  Distribution of mef(A) in gram-positive bacteria from healthy Portuguese children.

Authors:  Vicki A Luna; Marc Heiken; Kathleen Judge; Catherine Ulep; Nicole Van Kirk; Henrique Luis; Mario Bernardo; Jose Leitao; Marilyn C Roberts
Journal:  Antimicrob Agents Chemother       Date:  2002-08       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.